GWAS of 24 juvenile-onset Addison's disease cases in NSDTRs. Genome-wide significant association at chr27:29,724,286 in RESF1 — an immune gene silencing regulator. At least 41.7% of affected dogs had concurrent autoimmune conditions (thyroiditis, haemolytic anaemia, IBD), reframing this as Multiple Autoimmune Syndrome. Median survival: 2 years despite treatment.
First Asian population-level carrier frequency study for Imerslund-Gräsbeck Syndrome in 107 Border Collies from Thailand. CUBN exon 53 single-C deletion causes selective vitamin B12 malabsorption and neurological deterioration. Carrier rate: 0.93%. PCR-based assay — clinically deployable without WGS.
New tool (SCOPE) for global admixture inference from WGS. 65-breed reference panel, 349 individuals. Accurate at low coverage. Provides error bounds on admixture estimates — not just point estimates. East Asian breeds entirely absent.
5,887-genome study of flavin-containing monooxygenases FMO1 and FMO3. Identified 7 nonsynonymous variants + 1 frameshift null allele in FMO3. Variants D253V, P358S, P448L each reduce enzyme activity ~50%. Null allele c.116delG likely eliminates FMO3 function entirely. Long-read sequencing used for haplotype phasing.
Comprehensive review of ivermectin toxicology. Central finding: MDR1/ABCB1-mediated P-glycoprotein efflux at the blood-brain barrier is the dominant neurotoxicity mechanism. Breed-specific susceptibility in herding breeds is genetically established and clinically tractable.
WGS of a Miniature Dachshund with clinical NCL (canine Batten disease equivalent). Homozygous for variants in 5 lysosome-related genes, 4 never before linked to NCL in any species. Causality unresolved — single gene or oligogenic. Single case — not reportable until peer-reviewed and replicated.
First standardised IMGT-compliant annotation of the immunoglobulin kappa locus across multiple dog breeds. Prior GWAS studies of immune diseases may have been confounded by IGK locus misrepresentation. Enables future immunogenomics GWAS to be conducted correctly.
RNA-seq + CYP activity comparison between dog and human hepatocytes under three drug exposures. Acetaminophen dramatically more toxic in dogs. CYP2B11 and CYP3A12 are the key canine CYPs (equivalents of human CYP2B6 and CYP3A4). Species-level metabolic differences confirmed at transcriptomic resolution.
Ancient breeds (low European admixture) show significantly longer lifespans and smaller litter sizes at equivalent body weight — consistent with more evolved somatic maintenance. Modern large breeds show adaptive lag in cancer suppression. Taiwan Dog and Shiba Inu specifically identified as ancient breeds with lifespan advantage.
WES of 36 matched FOSCC tumour/normal pairs using Felis_catus_9.0 as reference genome. FOSCC is the 4th most common feline malignancy, proposed as a model for human HNSCC due to biological and therapeutic similarities. Catalogues somatic mutations and identifies shared driver genes with human cancer.
Comprehensive review of feline alimentary (intestinal) lymphoma — the most common feline malignancy. Despite its prevalence, molecular landscape is "poorly characterised" and no large-scale multi-omics dataset exists. Low-grade alimentary lymphoma sits on a diagnostic spectrum with IBD — genetic risk factors could help distinguish these before biopsy.
Longitudinal MRI + ultrasound framework for monitoring cyst-level PKD progression in a single Persian cat over two years. Asymmetric cyst growth and coalescence events detected that were missed by standard total-kidney-volume metrics. Proof of concept, not population study.
Plasma proteomics in HCM-affected vs. healthy cats. HCM pathophysiology not fully understood despite known MYBPC3 cause in two breeds. Complement and extracellular matrix remodelling pathways identified. Moving toward blood-based tests that complement genetic screening.
112 cats (61 normal, 51 subclinical HCM) evaluated by 6-lead ECG. R wave amplitude and ST elevation as predictors — but ECG had limited accuracy. Echocardiography remains gold standard for HCM diagnosis. ECG is not a reliable intermediate screening step.
Editorial challenging meloxicam's use in cats, documenting suppressed acute kidney injury risk data from a manufacturer-sponsored trial. Cats lack functional UGT1A6 — cannot glucuronidate many NSAIDs, leading to drug accumulation. This is species-level biology, not individual variation.
Zoetis (NYSE: ZTS) entered a definitive agreement to buy Neogen's entire animal genomics business (GeneSeek) for $160M. Neogen's genomics unit generated ~$90M in FY2025 revenue and serves customers in 120+ countries from labs in the US, Brazil, Australia, China, and UK. Closes H2 2026. This is the second major genomics acquisition for Zoetis — they bought Basepaws for ~$90M in 2022. Neogen is selling to deleverage and refocus on food safety.
Follow: Watch where Zoetis deploys Neogen's infrastructure post-close. If they launch a Taiwan/Asia companion animal product in 2027, BiLiGene needs to be established with vet partnerships by then. Don't follow: Do not try to replicate Neogen's array-based model — it's being rolled into a giant. The strategic play is long-read sequencing + Asia reference panel, which Zoetis can't easily build without years of data. Own angle: Every Zoetis/Mars acquisition is a geographic consolidation story. BiLiGene's Taiwan/Asia moat gets more valuable each time an incumbent consolidates elsewhere.
Mars completed acquisition of Cerba HealthCare's stake in Cerba Vet (6 French/Swiss diagnostic labs, 140 employees) and ANTAGENE (Lyon-based leading European animal genetics firm, testing dogs/cats/horses/wildlife). These rolled into Mars Science & Diagnostics, which also owns Antech (90+ reference labs globally) and Wisdom Panel. Mars Petcare is a $50B+ division of $50B Mars Inc.
Follow: The "DNA → clinical recommendation → product" loop is correct. BiLiGene should build its own version: genotype → vet-integrated report → pharmacogenomics-informed dosing → supplement/diet recommendation. Don't follow: Do not compete on breed count or feature parity. Wisdom Panel has tested 5M pets. You cannot out-Wisdom Wisdom Panel. Own angle: Mars sells to Western customers through Western vet chains. The Asia vet channel is fragmented, local, and relationship-driven — exactly where a small focused operator beats a global giant.
Analyst estimates for the global pet DNA testing market cluster around $400–700M in 2025, with 9–10% CAGR projected to 2030–34. Grand View: $404M (2024) → $718M (2030). Precedence: $406M (2024) → $1.08B (2034). Coherent Market Insights gives Asia-Pacific a 27% share in 2026, second only to North America at 44%. The Asia-Pacific animal genetics market (broader) is projected at $2.45B by 2030, 7.1% CAGR.
Follow: Position around APAC growth narrative when speaking to investors or acquirers — the numbers support the thesis. Don't follow: Don't build a business plan predicated on the global market CAGR. That's where Zoetis and Mars play. BiLiGene's TAM is the slice of APAC they haven't touched yet — much smaller, but winnable. Own angle: Taiwan pet ownership is rising alongside China/SE Asia but with much higher disposable income per pet and stronger premium purchase behaviour. Taiwan is the best test market before regional expansion.
Global animal biotechnology market estimated at $34.6–36.19B in 2026 at ~10% CAGR. The oncology segment is scaling at 19.42% CAGR as checkpoint-inhibitor science and CAR-T therapies migrate from human to veterinary use (LEAH Labs doing canine CAR-T). North America holds 35.7% share; Asia-Pacific is the fastest-growing region at 13.9% CAGR through 2035. China's pet care market alone hit $23.52B in 2026.
Follow: Oncology is the right acquisition hook. Position the cancer genomics data asset as the feeder for the oncology therapeutics gold rush. Don't follow: Don't chase CAR-T or mAb development — wrong capital structure, wrong timeline. That's a $100M+ investment. Own angle: Companies developing canine cancer therapeutics (LEAH Labs, FidoCure, ImpriMed) all need germline-stratified patient populations to accelerate trials. BiLiGene's role is supplier, not competitor. Germline test → patient stratification → trial enrichment.
Veterinary AI diagnostics market expected to cross $936M in 2026, reaching $3.9B by 2035 at 17.25% CAGR. AI in animal health broadly: $1.57B (2024) → $6.98B (2033) at 18.49% CAGR. Key AI players include FidoCure (canine cancer genomics with a 2B+ datapoint dataset), ImpriMed ($35M raised, Mayo Clinic Platform accelerator graduate, expanding to human oncology), and Zoetis's own generative AI drug discovery initiative. North America holds 55% of the AI diagnostics market; APAC is the fastest-growing region.
Follow: Build the AI layer early — an LLM-powered personalised report engine is differentiating today, table-stakes in 24 months. BiLiGene already has this in the strategy. Ship it. Don't follow: Do not raise a venture round purely on the AI angle. Investors who funded FidoCure/ImpriMed at $100M+ valuations will not fund a 2nd or 3rd mover on the same thesis. The AI product serves the data asset, not the other way around. Own angle: FidoCure and ImpriMed sit downstream of germline data — they profile tumours but don't know the dog's inherited risk. BiLiGene's germline layer is upstream of both. Position as the input to their pipeline, not a competitor to their output.
Pet Tech sector has attracted $5.9B+ over the last 10 years; 2025 saw $346M across 37 equity rounds. Vet clinic networks dominate: Bond Vet, Modern Animal, Petfolk, Small Door Veterinary have collectively raised $668M. Lassie (Swedish pet insurance) closed $75M Series C in Feb 2026 — 3× its prior total funding. Loyal (dog longevity) raised $137.1M. Digitalis Ventures is the most active specialist investor (backed MoeGo, PetMedix, Companion, Gallant, Scribenote).
Follow: Recognise the capital reality — DTC pet genetics alone doesn't raise big venture rounds anymore. The exit is acquisition by a strategic (Zoetis, Mars, pharma), not an IPO. Plan accordingly. Don't follow: Don't copy the vet-clinic-network playbook. That's a real estate + labour business, not a genomics business. Different capital structure, different game. Own angle: BiLiGene's lean one-person operation reaching profitability at small scale is a feature, not a bug. It means you don't need venture capital to survive, which means you can hold out for a strategic exit on your timeline. Every month you operate profitably, your negotiating leverage compounds.
The DTC pet genetics market is a duopoly (Embark, Wisdom Panel) with a few specialist challengers (Basepaws/Zoetis for cats, Orivet for breeders). Wisdom Panel hit 5M+ pets tested in March 2025, making it the largest pet DNA dataset in existence. Embark, backed by Cornell University and $75M Series B funding, launched a Relative Finder feature in July 2025 — social/network effects play. Embark's revenue is projected to exceed $100M. All three operate on Illumina microarrays; none offers long-read sequencing; none has meaningful Asia coverage.
The business environment in 2026 is: incumbent consolidation (Zoetis, Mars), venture capital rotating from DTC genetics to vet clinics/insurance/therapeutics, AI as table stakes (not differentiation), and APAC as the undisputed fastest-growing region. Here's how BiLiGene should respond.
While the incumbents consolidate Western microarray-based pet genetics, BiLiGene builds the labeled APAC dataset they can't replicate, on a long-read platform they can't cheaply retrofit, as the supplier layer for the oncology boom — and stays lean enough to control the exit timing.